APEX1 and hepatocellular carcinoma: Based on the down-regulation of MAP2K6 in sh-APEX1-treated HCC cells and a positive correlation of expression of APEX1 and MAP2K6 in HCC tissues, we suggest that APEX1 enhances the malignant properties of HCC via MAP2K6.